Azathioprine or mercaptopurine‐induced acute pancreatitis is not a disease‐specific phenomenon
Aliment Pharmacol Ther 31, 1322–1329 Summary Background Several reports suggest an increased rate of adverse reactions to azathioprine in patients with Crohn’s disease. Aim To compare the incidence of thiopurine‐induced acute pancreatitis in patients with inflammatory bowel disease (IBD) with that...
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 2010-06, Vol.31 (12), p.1322-1329 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1329 |
|---|---|
| container_issue | 12 |
| container_start_page | 1322 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 31 |
| creator | VAN GEENEN, E. J. M. DE BOER, N. K. H. STASSEN, P. LINSKENS, R. K. BRUNO, M. J. MULDER, C. J. J. STEGEMAN, C. A. VAN BODEGRAVEN, A. A. |
| description | Aliment Pharmacol Ther 31, 1322–1329
Summary
Background Several reports suggest an increased rate of adverse reactions to azathioprine in patients with Crohn’s disease.
Aim To compare the incidence of thiopurine‐induced acute pancreatitis in patients with inflammatory bowel disease (IBD) with that in patients with vasculitis.
Methods This retrospective analysis was performed using data collected in three databases by two university hospitals (241 patients with IBD and 108 patients with vasculitis) and one general district hospital (72 patients with IBD).
Results The cumulative incidence of thiopurine‐induced acute pancreatitis in Crohn’s disease equalled that of ulcerative colitis (UC) (2.6% vs. 3.7%) and this did not differ from vasculitis patients (2.6% vs.1.9%). In addition, the cumulative incidence of thiopurine‐induced acute pancreatitis in UC patients was not different from that in vasculitis patients. In the IBD group, 100% of thiopurine‐induced acute pancreatitis patients were women, whereas in the vasculitis group the two observed thiopurine‐induced acute pancreatitis cases (n = 2 of 2) concerned were men (P = 0.012).
Conclusions In this study, the alleged higher cumulative incidence of thiopurine‐induced acute pancreatitis in Crohn’s disease compared with vasculitis or UC patients was not confirmed. Female gender appears to be a risk factor for developing thiopurine‐induced acute pancreatitis in IBD patients. |
| doi_str_mv | 10.1111/j.1365-2036.2010.04287.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_00552542v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733647940</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5107-778bf40187acf7d0d182649944c94d8408bb8aa719e874f55e506e198134c3bf3</originalsourceid><addsrcrecordid>eNqNkd2K1DAUgIO4uOPqK0hAZPGi48lfk154MSzqCgPrxXod0jRlMrRNTVrd3SsfwWf0SUydcQSvDAkJJ99JzuFDCBNYkzze7NeElaKgwMo1hRwFTpVc3z1Cq9PFY7QCWlYFVYSdo6cp7QGglECfoHMKlNKKsBWqNw9m2vkwRj84HCLuXbRmnMI4L5Gf33_4oZmta7Cx8-TwaAYbnZn85BPOcwgTNrjxyZm00Gl01rfe4nHnhtDnNTxDZ63pknt-3C_Q5_fvbq-ui-3Nh49Xm21hBQFZSKnqlgNR0thWNtAQRUteVZzbijeKg6prZYwklVOSt0I4AaUjVW6PW1a37AK9Pry7M53O_fQm3utgvL7ebPUSAxCCCk6_ksxeHtgxhi-zS5PufbKu68zgwpy0ZKzksuKQyZf_kPswxyE3oikRhAshSpopdaBsDClF154KIKAXZXqvFzN6MaMXZfq3Mn2XU18cP5jr3jWnxD-OMvDqCJhkTdfGrMCnvxyVkimlMvf2wH3znbv_7wL05tPtcmK_ALbjslk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2151455562</pqid></control><display><type>article</type><title>Azathioprine or mercaptopurine‐induced acute pancreatitis is not a disease‐specific phenomenon</title><source>MEDLINE</source><source>Wiley Online Library Journals</source><source>Wiley Free Archive</source><source>EZB Electronic Journals Library</source><creator>VAN GEENEN, E. J. M. ; DE BOER, N. K. H. ; STASSEN, P. ; LINSKENS, R. K. ; BRUNO, M. J. ; MULDER, C. J. J. ; STEGEMAN, C. A. ; VAN BODEGRAVEN, A. A.</creator><creatorcontrib>VAN GEENEN, E. J. M. ; DE BOER, N. K. H. ; STASSEN, P. ; LINSKENS, R. K. ; BRUNO, M. J. ; MULDER, C. J. J. ; STEGEMAN, C. A. ; VAN BODEGRAVEN, A. A.</creatorcontrib><description>Aliment Pharmacol Ther 31, 1322–1329
Summary
Background Several reports suggest an increased rate of adverse reactions to azathioprine in patients with Crohn’s disease.
Aim To compare the incidence of thiopurine‐induced acute pancreatitis in patients with inflammatory bowel disease (IBD) with that in patients with vasculitis.
Methods This retrospective analysis was performed using data collected in three databases by two university hospitals (241 patients with IBD and 108 patients with vasculitis) and one general district hospital (72 patients with IBD).
Results The cumulative incidence of thiopurine‐induced acute pancreatitis in Crohn’s disease equalled that of ulcerative colitis (UC) (2.6% vs. 3.7%) and this did not differ from vasculitis patients (2.6% vs.1.9%). In addition, the cumulative incidence of thiopurine‐induced acute pancreatitis in UC patients was not different from that in vasculitis patients. In the IBD group, 100% of thiopurine‐induced acute pancreatitis patients were women, whereas in the vasculitis group the two observed thiopurine‐induced acute pancreatitis cases (n = 2 of 2) concerned were men (P = 0.012).
Conclusions In this study, the alleged higher cumulative incidence of thiopurine‐induced acute pancreatitis in Crohn’s disease compared with vasculitis or UC patients was not confirmed. Female gender appears to be a risk factor for developing thiopurine‐induced acute pancreatitis in IBD patients.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/j.1365-2036.2010.04287.x</identifier><identifier>PMID: 20222913</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>6-Mercaptopurine ; Acute Disease ; Adolescent ; Adult ; Aged ; Antimetabolites - adverse effects ; Azathioprine ; Azathioprine - adverse effects ; Biological and medical sciences ; Crohn Disease - drug therapy ; Digestive system ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Incidence ; Inflammatory bowel disease ; Inflammatory bowel diseases ; Intestine ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; Mercaptopurine - adverse effects ; Middle Aged ; Other diseases. Semiology ; Pancreatitis ; Pancreatitis - chemically induced ; Pharmacology. Drug treatments ; Retrospective Studies ; Risk factors ; Statistics as Topic ; Ulcerative colitis ; Vasculitis ; Young Adult</subject><ispartof>Alimentary pharmacology & therapeutics, 2010-06, Vol.31 (12), p.1322-1329</ispartof><rights>2010 VU University Medical Centre</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Wiley Subscription Services, Inc. Jun 2010</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5107-778bf40187acf7d0d182649944c94d8408bb8aa719e874f55e506e198134c3bf3</citedby><cites>FETCH-LOGICAL-c5107-778bf40187acf7d0d182649944c94d8408bb8aa719e874f55e506e198134c3bf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2036.2010.04287.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2036.2010.04287.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22773888$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20222913$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-00552542$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>VAN GEENEN, E. J. M.</creatorcontrib><creatorcontrib>DE BOER, N. K. H.</creatorcontrib><creatorcontrib>STASSEN, P.</creatorcontrib><creatorcontrib>LINSKENS, R. K.</creatorcontrib><creatorcontrib>BRUNO, M. J.</creatorcontrib><creatorcontrib>MULDER, C. J. J.</creatorcontrib><creatorcontrib>STEGEMAN, C. A.</creatorcontrib><creatorcontrib>VAN BODEGRAVEN, A. A.</creatorcontrib><title>Azathioprine or mercaptopurine‐induced acute pancreatitis is not a disease‐specific phenomenon</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Aliment Pharmacol Ther 31, 1322–1329
Summary
Background Several reports suggest an increased rate of adverse reactions to azathioprine in patients with Crohn’s disease.
Aim To compare the incidence of thiopurine‐induced acute pancreatitis in patients with inflammatory bowel disease (IBD) with that in patients with vasculitis.
Methods This retrospective analysis was performed using data collected in three databases by two university hospitals (241 patients with IBD and 108 patients with vasculitis) and one general district hospital (72 patients with IBD).
Results The cumulative incidence of thiopurine‐induced acute pancreatitis in Crohn’s disease equalled that of ulcerative colitis (UC) (2.6% vs. 3.7%) and this did not differ from vasculitis patients (2.6% vs.1.9%). In addition, the cumulative incidence of thiopurine‐induced acute pancreatitis in UC patients was not different from that in vasculitis patients. In the IBD group, 100% of thiopurine‐induced acute pancreatitis patients were women, whereas in the vasculitis group the two observed thiopurine‐induced acute pancreatitis cases (n = 2 of 2) concerned were men (P = 0.012).
Conclusions In this study, the alleged higher cumulative incidence of thiopurine‐induced acute pancreatitis in Crohn’s disease compared with vasculitis or UC patients was not confirmed. Female gender appears to be a risk factor for developing thiopurine‐induced acute pancreatitis in IBD patients.</description><subject>6-Mercaptopurine</subject><subject>Acute Disease</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antimetabolites - adverse effects</subject><subject>Azathioprine</subject><subject>Azathioprine - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Crohn Disease - drug therapy</subject><subject>Digestive system</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Incidence</subject><subject>Inflammatory bowel disease</subject><subject>Inflammatory bowel diseases</subject><subject>Intestine</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mercaptopurine - adverse effects</subject><subject>Middle Aged</subject><subject>Other diseases. Semiology</subject><subject>Pancreatitis</subject><subject>Pancreatitis - chemically induced</subject><subject>Pharmacology. Drug treatments</subject><subject>Retrospective Studies</subject><subject>Risk factors</subject><subject>Statistics as Topic</subject><subject>Ulcerative colitis</subject><subject>Vasculitis</subject><subject>Young Adult</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkd2K1DAUgIO4uOPqK0hAZPGi48lfk154MSzqCgPrxXod0jRlMrRNTVrd3SsfwWf0SUydcQSvDAkJJ99JzuFDCBNYkzze7NeElaKgwMo1hRwFTpVc3z1Cq9PFY7QCWlYFVYSdo6cp7QGglECfoHMKlNKKsBWqNw9m2vkwRj84HCLuXbRmnMI4L5Gf33_4oZmta7Cx8-TwaAYbnZn85BPOcwgTNrjxyZm00Gl01rfe4nHnhtDnNTxDZ63pknt-3C_Q5_fvbq-ui-3Nh49Xm21hBQFZSKnqlgNR0thWNtAQRUteVZzbijeKg6prZYwklVOSt0I4AaUjVW6PW1a37AK9Pry7M53O_fQm3utgvL7ebPUSAxCCCk6_ksxeHtgxhi-zS5PufbKu68zgwpy0ZKzksuKQyZf_kPswxyE3oikRhAshSpopdaBsDClF154KIKAXZXqvFzN6MaMXZfq3Mn2XU18cP5jr3jWnxD-OMvDqCJhkTdfGrMCnvxyVkimlMvf2wH3znbv_7wL05tPtcmK_ALbjslk</recordid><startdate>201006</startdate><enddate>201006</enddate><creator>VAN GEENEN, E. J. M.</creator><creator>DE BOER, N. K. H.</creator><creator>STASSEN, P.</creator><creator>LINSKENS, R. K.</creator><creator>BRUNO, M. J.</creator><creator>MULDER, C. J. J.</creator><creator>STEGEMAN, C. A.</creator><creator>VAN BODEGRAVEN, A. A.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><general>Wiley Subscription Services, Inc</general><general>Wiley</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope></search><sort><creationdate>201006</creationdate><title>Azathioprine or mercaptopurine‐induced acute pancreatitis is not a disease‐specific phenomenon</title><author>VAN GEENEN, E. J. M. ; DE BOER, N. K. H. ; STASSEN, P. ; LINSKENS, R. K. ; BRUNO, M. J. ; MULDER, C. J. J. ; STEGEMAN, C. A. ; VAN BODEGRAVEN, A. A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5107-778bf40187acf7d0d182649944c94d8408bb8aa719e874f55e506e198134c3bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>6-Mercaptopurine</topic><topic>Acute Disease</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antimetabolites - adverse effects</topic><topic>Azathioprine</topic><topic>Azathioprine - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Crohn Disease - drug therapy</topic><topic>Digestive system</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Incidence</topic><topic>Inflammatory bowel disease</topic><topic>Inflammatory bowel diseases</topic><topic>Intestine</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mercaptopurine - adverse effects</topic><topic>Middle Aged</topic><topic>Other diseases. Semiology</topic><topic>Pancreatitis</topic><topic>Pancreatitis - chemically induced</topic><topic>Pharmacology. Drug treatments</topic><topic>Retrospective Studies</topic><topic>Risk factors</topic><topic>Statistics as Topic</topic><topic>Ulcerative colitis</topic><topic>Vasculitis</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VAN GEENEN, E. J. M.</creatorcontrib><creatorcontrib>DE BOER, N. K. H.</creatorcontrib><creatorcontrib>STASSEN, P.</creatorcontrib><creatorcontrib>LINSKENS, R. K.</creatorcontrib><creatorcontrib>BRUNO, M. J.</creatorcontrib><creatorcontrib>MULDER, C. J. J.</creatorcontrib><creatorcontrib>STEGEMAN, C. A.</creatorcontrib><creatorcontrib>VAN BODEGRAVEN, A. A.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VAN GEENEN, E. J. M.</au><au>DE BOER, N. K. H.</au><au>STASSEN, P.</au><au>LINSKENS, R. K.</au><au>BRUNO, M. J.</au><au>MULDER, C. J. J.</au><au>STEGEMAN, C. A.</au><au>VAN BODEGRAVEN, A. A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Azathioprine or mercaptopurine‐induced acute pancreatitis is not a disease‐specific phenomenon</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2010-06</date><risdate>2010</risdate><volume>31</volume><issue>12</issue><spage>1322</spage><epage>1329</epage><pages>1322-1329</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Aliment Pharmacol Ther 31, 1322–1329
Summary
Background Several reports suggest an increased rate of adverse reactions to azathioprine in patients with Crohn’s disease.
Aim To compare the incidence of thiopurine‐induced acute pancreatitis in patients with inflammatory bowel disease (IBD) with that in patients with vasculitis.
Methods This retrospective analysis was performed using data collected in three databases by two university hospitals (241 patients with IBD and 108 patients with vasculitis) and one general district hospital (72 patients with IBD).
Results The cumulative incidence of thiopurine‐induced acute pancreatitis in Crohn’s disease equalled that of ulcerative colitis (UC) (2.6% vs. 3.7%) and this did not differ from vasculitis patients (2.6% vs.1.9%). In addition, the cumulative incidence of thiopurine‐induced acute pancreatitis in UC patients was not different from that in vasculitis patients. In the IBD group, 100% of thiopurine‐induced acute pancreatitis patients were women, whereas in the vasculitis group the two observed thiopurine‐induced acute pancreatitis cases (n = 2 of 2) concerned were men (P = 0.012).
Conclusions In this study, the alleged higher cumulative incidence of thiopurine‐induced acute pancreatitis in Crohn’s disease compared with vasculitis or UC patients was not confirmed. Female gender appears to be a risk factor for developing thiopurine‐induced acute pancreatitis in IBD patients.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>20222913</pmid><doi>10.1111/j.1365-2036.2010.04287.x</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2010-06, Vol.31 (12), p.1322-1329 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_00552542v1 |
| source | MEDLINE; Wiley Online Library Journals; Wiley Free Archive; EZB Electronic Journals Library |
| subjects | 6-Mercaptopurine Acute Disease Adolescent Adult Aged Antimetabolites - adverse effects Azathioprine Azathioprine - adverse effects Biological and medical sciences Crohn Disease - drug therapy Digestive system Female Gastroenterology. Liver. Pancreas. Abdomen Humans Incidence Inflammatory bowel disease Inflammatory bowel diseases Intestine Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Mercaptopurine - adverse effects Middle Aged Other diseases. Semiology Pancreatitis Pancreatitis - chemically induced Pharmacology. Drug treatments Retrospective Studies Risk factors Statistics as Topic Ulcerative colitis Vasculitis Young Adult |
| title | Azathioprine or mercaptopurine‐induced acute pancreatitis is not a disease‐specific phenomenon |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T16%3A07%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Azathioprine%20or%20mercaptopurine%E2%80%90induced%20acute%20pancreatitis%20is%20not%20a%20disease%E2%80%90specific%20phenomenon&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=VAN%20GEENEN,%20E.%20J.%20M.&rft.date=2010-06&rft.volume=31&rft.issue=12&rft.spage=1322&rft.epage=1329&rft.pages=1322-1329&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/j.1365-2036.2010.04287.x&rft_dat=%3Cproquest_hal_p%3E733647940%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2151455562&rft_id=info:pmid/20222913&rfr_iscdi=true |